nach oben

Seminars in Immunopathology

Erschienen in:

01.03.2012 | Review

Exploring Staphylococcus aureus pathways to disease for vaccine development

verfasst von: Andrea DeDent, Hwan Keun Kim, Dominique Missiakas, Olaf Schneewind

Erschienen in: Seminars in Immunopathology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Staphylococcus aureus is a commensal of the human skin or nares and a pathogen that frequently causes skin and soft tissue infections as well as bacteremia and sepsis. Recent efforts in understanding the molecular mechanisms of pathogenesis revealed key virulence strategies of S. aureus in host tissues: bacterial scavenging of iron, induction of coagulation pathways to promote staphylococcal agglutination in the vasculature, and suppression of innate and adaptive immune responses. Advances in all three areas have been explored for opportunities in vaccine design in an effort to identify the critical protective antigens of S. aureus. Human clinical trials with specific subunit vaccines have failed, yet provide important insights for the design of future trials that must address the current epidemic of S. aureus infections with drug-resistant isolates (MRSA, methicillin-resistant S. aureus).

Peacock SJ, de Silva I, Lowy FD (2001) What determines nasal carriage of Staphylococcus aureus? Trends Microbiol 9:605–610PubMedCrossRef

Neu HC (1992) The crisis in antibiotic resistance. Science 257:1064–1073PubMedCrossRef

Chambers HF, Deleo FR (2009) Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 7:629–641PubMedCrossRef

Chambers HF (2001) The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 7:178–182PubMedCrossRef

Deleo FR, Otto M, Kreiswirth BN, HF Chambers Community-associated meticillin-resistant Staphylococcus aureus. Lancet 375:1557–1568

Klevens RM, Edwards JR, Gaynes RP (2008) The impact of antimicrobial-resistant, health care-associated infections on mortality in the United States. Clin Infect Dis 47:927–930PubMedCrossRef

Projan SJ, Nesin M, Dunman PM (2006) Staphylococcal vaccines and immunotherapy: to dream the impossible dream? Curr Opin Pharmacol 6:473–479PubMedCrossRef

Lowy FD (1998) Staphylococcus aureus infections. N Engl J Med 339:520–532PubMedCrossRef

Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, Yeoh H, Law D, Robbins JB, Schneerson R et al (2002) Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 346:491–496PubMedCrossRef

10.

DeJonge M, Burchfield D, Bloom B, Duenas M, Walker W, Polak M, Jung E, Millard D, Schelonka R, Eyal F et al (2007) Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J Pediatr 151:260–265, 265 e1PubMedCrossRef

11.

Kuklin NA, Clark DJ, Secore S, Cook J, Cope LD, McNeely T, Noble L, Brown MJ, Zorman JK, Wang XM et al (2006) A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun 74:2215–2223PubMedCrossRef

12.

Fattom AI, Horwith G, Fuller S, Propst M, Naso R (2004) Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials. Vaccine 22:880–887PubMedCrossRef

13.

Finch CA (1959) Body iron exchange in man. J Clin Invest 38:392–396PubMedCrossRef

14.

Huff RL, Hennessy TG, Austin RE, Garcia JF, Roberts BM, Lawrence JH (1950) Plasma and red cell iron turnover in normal subjects and in patients having various hematopoietic disorders. J Clin Invest 29:1041–1052PubMedCrossRef

15.

Morgan WT, Liem HH, Sutor RP, Muller-Ebergard U (1976) Transfer of heme from heme–albumin to hemopexin. Biochim Biophys Acta 444:435–445PubMedCrossRef

16.

Giblett ER (1968) Recent advances in heptoglobin and transferrin genetics. Bibl Haematol 29:10–20PubMed

17.

Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, Moestrup SK (2001) Identification of the haemoglobin scavenger receptor. Nature 409:198–201PubMedCrossRef

18.

Uchida T, Akitsuki T, Kimura H, Tanaka T, Matsuda S, Kariyone S (1983) Relationship among plasma iron, plasma iron turnover, and reticuloendothelial iron release. Blood 61:799–802PubMed

19.

Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, Loreal O (2001) A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 276:7811–7819PubMedCrossRef

20.

Park CH, Valore EV, Waring AJ, Ganz T (2001) Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 276:7806–7810PubMedCrossRef

21.

Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, Adermann K (2000) LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 480:147–150PubMedCrossRef

22.

Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, Vaulont S (2001) Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA 98:8780–8785PubMedCrossRef

23.

Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306:2090–2093PubMedCrossRef

24.

Knutson MD, Oukka M, Koss LM, Aydemir F, Wessling-Resnick M (2005) Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. Proc Natl Acad Sci USA 102:1324–1328PubMedCrossRef

25.

Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S (2002) The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 110:1037–1044PubMed

26.

Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T (2003) Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101:2461–2463PubMedCrossRef

27.

Weinberg ED (1984) Iron withholding: a defense against infection and neoplasia. Physiol Rev 64:65–102PubMed

28.

Rivera S, Nemeth E, Gabayan V, Lopez MA, Farshidi D, Ganz T (2005) Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood 106:2196–2199PubMedCrossRef

29.

Pietrangelo A (2006) Molecular insights into the pathogenesis of hereditary haemochromatosis. Gut 55:564–568PubMedCrossRef

30.

Van Snick JL, Masson PL, Heremans JF (1974) The involvement of lactoferrin in the hyposideremia of acute inflammation. J Exp Med 140:1068–1084PubMedCrossRef

31.

van Snick JL, Markowetz B, Masson PL (1977) The ingestion and digestion of human lactoferrin by mouse peritoneal macrophages and the transfer of its iron into ferritin. J Exp Med 146:817–827PubMedCrossRef

32.

Fluckinger M, Haas H, Merschak P, Glasgow BJ, Redl B (2004) Human tear lipocalin exhibits antimicrobial activity by scavenging microbial siderophores. Antimicrob Agents Chemother 48:3367–3372PubMedCrossRef

33.

Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, Akira S, Aderem A (2004) Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 432:917–921PubMedCrossRef

34.

Ford FA, Mouratidou T, Wademan SE, Fraser RB (2009) Effect of the introduction of 'Healthy Start' on dietary behaviour during and after pregnancy: early results from the 'before and after' Sheffield study. Br J Nutr 101:1828–1836PubMedCrossRef

35.

Eaton JW, Brandt P, Mahoney JR, Lee JT Jr (1982) Haptoglobin: a natural bacteriostat. Science 215:691–693PubMedCrossRef

36.

Moore DG, Earhart CF (1981) Specific inhibition of Escherichia coli ferrienterochelin uptake by a normal human serum immunoglobulin. Infect Immun 31:631–635PubMed

37.

Bullen JJ, Rogers HJ, Griffiths E (1978) Role of iron in bacterial infection. Curr Top Microbiol Immunol 80:1–35PubMedCrossRef

38.

Horsburgh MJ, Clements MO, Crossley H, Ingham E, Foster SJ (2001) PerR controls oxidative stress resistance and iron storage proteins and is required for virulence in Staphylococcus aureus. Infect Immun 69:3744–3754PubMedCrossRef

39.

Horsburgh MJ, Wharton SJ, Cox AG, Ingham E, Peacock S, Foster SJ (2002) MntR modulates expression of the PerR regulon and superoxide resistance in Staphylococcus aureus through control of manganese uptake. Mol Microbiol 44:1269–1286PubMedCrossRef

40.

Hill PJ, Cockayne A, Landers P, Morrissey JA, Sims CM, Williams P (1998) SirR, a novel iron-dependent repressor in Staphylococcus epidermidis. Infect Immun 66:4123–4129PubMed

41.

Xiong A, Singh VK, Cabrera G (2000) RK Jayaswal: Molecular characterization of the ferric-uptake regulator, fur, from Staphylococcus aureus. Microbiology 146(Pt 3):659–668PubMed

42.

Horsburgh MJ, Ingham E, Foster SJ (2001) In Staphylococcus aureus, fur is an interactive regulator with PerR, contributes to virulence, and is necessary for oxidative stress resistance through positive regulation of catalase and iron homeostasis. J Bacteriol 183:468–475PubMedCrossRef

43.

Torres VJ, Attia AS, Mason WJ, Hood MI, Corbin BD, Beasley FC, Anderson KL, Stauff DL, McDonald WH, Zimmerman LJ et al Staphylococcus aureus fur regulates the expression of virulence factors that contribute to the pathogenesis of pneumonia. Infect Immun 78:1618–1628

44.

Stauff DL, Bagaley D, Torres VJ, Joyce R, Anderson KL, Kuechenmeister L, Dunman PM, Skaar EP (2008) Staphylococcus aureus HrtA is an ATPase required for protection against heme toxicity and prevention of a transcriptional heme stress response. J Bacteriol 190:3588–3596PubMedCrossRef

45.

Stauff DL, Torres VJ, Skaar EP (2007) Signaling and DNA-binding activities of the Staphylococcus aureus HssR-HssS two-component system required for heme sensing. J Biol Chem 282:26111–26121PubMedCrossRef

46.

Torres VJ, Stauff DL, Pishchany G, Bezbradica JS, Gordy LE, Iturregui J, Anderson KL, Dunman PM, Joyce S, Skaar EP (2007) A Staphylococcus aureus regulatory system that responds to host heme and modulates virulence. Cell Host Microbe 1:109–119PubMedCrossRef

47.

Attia AS, Benson MA, Stauff DL, Torres VJ, Skaar EP Membrane damage elicits an immunomodulatory program in Staphylococcus aureus. PLoS Pathog 6:e1000802

48.

Crosa JH, Walsh CT (2002) Genetics and assembly line enzymology of siderophore biosynthesis in bacteria. Microbiol Mol Biol Rev 66:223–249PubMedCrossRef

49.

Challis GL (2005) A widely distributed bacterial pathway for siderophore biosynthesis independent of nonribosomal peptide synthetases. Chembiochem 6:601–611PubMedCrossRef

50.

Cotton JL, Tao J, Balibar CJ (2009) Identification and characterization of the Staphylococcus aureus gene cluster coding for staphyloferrin A. Biochemistry 48:1025–1035PubMedCrossRef

51.

Dale SE, Doherty-Kirby A, Lajoie G, Heinrichs DE (2004) Role of siderophore biosynthesis in virulence of Staphylococcus aureus: identification and characterization of genes involved in production of a siderophore. Infect Immun 72:29–37PubMedCrossRef

52.

Modun B, Evans RW, Joannou CL, Williams P (1998) Receptor-mediated recognition and uptake of iron from human transferrin by Staphylococcus aureus and Staphylococcus epidermidis. Infect Immun 66:3591–3596PubMed

53.

Beasley FC, Vines ED, Grigg JC, Zheng Q, Liu S, Lajoie GA, Murphy ME, Heinrichs DE (2009) Characterization of staphyloferrin A biosynthetic and transport mutants in Staphylococcus aureus. Mol Microbiol 72:947–963PubMedCrossRef

54.

Dale SE, Sebulsky MT, Heinrichs DE (2004) Involvement of SirABC in iron-siderophore import in Staphylococcus aureus. J Bacteriol 186:8356–8362PubMedCrossRef

55.

Grigg JC, Cheung J, Heinrichs DE, Murphy ME Specificity of Staphyloferrin B recognition by the SirA receptor from Staphylococcus aureus. J Biol Chem 285:34579–34588

56.

Skaar EP, Humayun M, Bae T, DeBord KL, Schneewind O (2004) Iron-source preference of Staphylococcus aureus infections. Science 305:1626–1628PubMedCrossRef

57.

Sebulsky MT, Hohnstein D, Hunter MD, Heinrichs DE (2000) Identification and characterization of a membrane permease involved in iron-hydroxamate transport in Staphylococcus aureus. J Bacteriol 182:4394–4400PubMedCrossRef

58.

Sebulsky MT, Heinrichs DE (2001) Identification and characterization of fhuD1 and fhuD2, two genes involved in iron-hydroxamate uptake in Staphylococcus aureus. J Bacteriol 183:4994–5000PubMedCrossRef

59.

Beasley FC, Marolda CL, Cheung J, Buac S, Heinrichs DE Staphylococcus aureus transporters Hts, Sir, and Sst capture iron liberated from human transferrin by Staphyloferrin A, Staphyloferrin B, and catecholamine stress hormones, respectively, and contribute to virulence. Infect Immun 79:2345–2355

60.

Mazmanian SK, Skaar EP, Gaspar AH, Humayun M, Gornicki P, Jelenska J, Joachmiak A, Missiakas DM, Schneewind O (2003) Passage of heme-iron across the envelope of Staphylococcus aureus. Science 299:906–909PubMedCrossRef

61.

Mazmanian SK, Ton-That H, Su K, Schneewind O (2002) An iron-regulated sortase anchors a class of surface protein during Staphylococcus aureus pathogenesis. Proc Natl Acad Sci USA 99:2293–2298PubMedCrossRef

62.

Torres VJ, Pishchany G, Humayun M, Schneewind O, Skaar EP (2006) Staphylococcus aureus IsdB is a hemoglobin receptor required for heme iron utilization. J Bacteriol 188:8421–8429PubMedCrossRef

63.

Dryla A, Gelbmann D, von Gabain A, Nagy E (2003) Identification of a novel iron regulated staphylococcal surface protein with haptoglobin-haemoglobin binding activity. Mol Microbiol 49:37–53PubMedCrossRef

64.

Pishchany G, Dickey SE, Skaar EP (2009) Subcellular localization of the Staphylococcus aureus heme iron transport components IsdA and IsdB. Infect Immun 77:2624–2634PubMedCrossRef

65.

Muryoi N, Tiedemann MT, Pluym M, Cheung J, Heinrichs DE, Stillman MJ (2008) Demonstration of the iron-regulated surface determinant (Isd) heme transfer pathway in Staphylococcus aureus. J Biol Chem 283:28125–28136PubMedCrossRef

66.

Liu M, Tanaka WN, Zhu H, Xie G, Dooley DM, Lei B (2008) Direct hemin transfer from IsdA to IsdC in the iron-regulated surface determinant (Isd) heme acquisition system of Staphylococcus aureus. J Biol Chem 283:6668–6676PubMedCrossRef

67.

Tiedemann MT, Muryoi N, Heinrichs DE, Stillman MJ (2008) Iron acquisition by the haem-binding Isd proteins in Staphylococcus aureus: studies of the mechanism using magnetic circular dichroism. Biochem Soc Trans 36:1138–1143PubMedCrossRef

68.

Pluym M, Vermeiren CL, Mack J, Heinrichs DE, Stillman MJ (2007) Heme binding properties of Staphylococcus aureus IsdE. Biochemistry 46:12777–12787PubMedCrossRef

69.

Mack J, Vermeiren C, Heinrichs DE, Stillman MJ (2004) In vivo heme scavenging by Staphylococcus aureus IsdC and IsdE proteins. Biochem Biophys Res Commun 320:781–788PubMedCrossRef

70.

Wu R, Skaar EP, Zhang R, Joachimiak G, Gornicki P, Schneewind O, Joachimiak A (2005) Staphylococcus aureus IsdG and IsdI, heme-degrading enzymes with structural similarity to monooxygenases. J Biol Chem 280:2840–2846PubMedCrossRef

71.

Skaar EP, Gaspar AH, Schneewind O (2004) IsdG and IsdI, heme-degrading enzymes in the cytoplasm of Staphylococcus aureus. J Biol Chem 279:436–443PubMedCrossRef

72.

Kim HK, DeDent A, Cheng AG, McAdow M, Bagnoli F, Missiakas DM, Schneewind O IsdA and IsdB antibodies protect mice against Staphylococcus aureus abscess formation and lethal challenge. Vaccine 28:6382–6392

73.

Cheng AG, Kim HK, Burts ML, Krausz T, Schneewind O, Missiakas DM (2009) Genetic requirements for Staphylococcus aureus abscess formation and persistence in host tissues. FASEB J 23:3393–3404PubMedCrossRef

74.

Clarke SR, Brummell KJ, Horsburgh MJ, McDowell PW, Mohamad SA, Stapleton MR, Acevedo J, Read RC, Day NP, Peacock SJ et al (2006) Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage. J Infect Dis 193:1098–1108PubMedCrossRef

75.

Etz H, Minh DB, Henics T, Dryla A, Winkler B, Triska C, Boyd AP, Sollner J, Schmidt W, von Ahsen U et al (2002) Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc Natl Acad Sci USA 99:6573–6578PubMedCrossRef

76.

Stranger-Jones YK, Bae T, Schneewind O (2006) Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci USA 103:16942–16947PubMedCrossRef

77.

Raedler MD, Heyne S, Wagner E, Shalkowski SK, Secore S, Anderson AS, Cook J, Cope L, McNeely T, Retzlaff M et al (2009) Serologic assay to quantify human immunoglobulin G antibodies to the Staphylococcus aureus iron surface determinant B antigen. Clin Vaccine Immunol 16:739–748PubMedCrossRef

78.

Brown M, Kowalski R, Zorman J, Wang XM, Towne V, Zhao Q, Secore S, Finnefrock AC, Ebert T, Pancari G et al (2009) Selection and characterization of murine monoclonal antibodies to Staphylococcus aureus iron-regulated surface determinant B with functional activity in vitro and in vivo. Clin Vaccine Immunol 16:1095–1104PubMedCrossRef

79.

Ebert T, Smith S, Pancari G, Clark D, Hampton R, Secore S, Towne V, Fan H, Wang XM, Wu X, et al A fully human monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB) with functional activity in vitro and in vivo. Hum Antibodies 19:113–128

80.

Smith JF, Kowalski R, Esser MT, Brown MJ, Bryan JT (2008) Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11. Hum Vaccin 4:134–142PubMedCrossRef

81.

Khan FA, Fisher MA, Khakoo RA (2007) Association of hemochromatosis with infectious diseases: expanding spectrum. Int J Infect Dis 11:482–487PubMedCrossRef

82.

Kumar V, Abbas AK, Fausto N, Aster JC (eds) (2010) Robbins and Cotran pathologic basis of disease, 8th edn. Saunders Elsevier, Philadelphia

83.

Foster TJ (2009) Colonization and infection of the human host by staphylococci: adhesion, survival and immune evasion. Vet Dermatol 20:456–470PubMedCrossRef

84.

Palazzolo-Ballance AM, Reniere ML, Braughton KR, Sturdevant DE, Otto M, Kreiswirth BN, Skaar EP, DeLeo FR (2008) Neutrophil microbicides induce a pathogen survival response in community-associated methicillin-resistant Staphylococcus aureus. J Immunol 180:500–509PubMed

85.

Miajlovic H, Zapotoczna M, Geoghegan JA, Kerrigan SW, Speziale P, Foster TJ Direct interaction of iron-regulated surface determinant IsdB of Staphylococcus aureus with the GPIIb/IIIa receptor on platelets. Microbiology 156:920–928

86.

Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411–415PubMedCrossRef

87.

Coller BS, Peerschke EI, Scudder LE, Sullivan CA (1983) Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand factor. Blood 61:99–110PubMed

88.

Bennett JS, Shattil SJ, Power JW, Gartner TK (1988) Interaction of fibrinogen with its platelet receptor. Differential effects of alpha and gamma chain fibrinogen peptides on the glycoprotein IIb–IIIa complex. J Biol Chem 263:12948–12953PubMed

89.

Cook JJ, Trybulec M, Lasz EC, Khan S, Niewiarowski S (1992) Binding of glycoprotein IIIa-derived peptide 217–231 to fibrinogen and von Willebrand factors and its inhibition by platelet glycoprotein IIb/IIIa complex. Biochim Biophys Acta 1119:312–321PubMedCrossRef

90.

Adams RL, Bird RJ (2009) Review article: Coagulation cascade and therapeutics update: relevance to nephrology. Part 1: overview of coagulation, thrombophilias and history of anticoagulants. Nephrology (Carlton) 14:462–470CrossRef

91.

Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y (1999) Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 96:2311–2315PubMedCrossRef

92.

Giesen PL, Nemerson Y (2000) Tissue factor on the loose. Semin Thromb Hemost 26:379–384PubMedCrossRef

93.

Lutz BR, Fulton GP, Akers RP (1951) White thromboembolism in the hamster cheek pouch after trauma, infection and neoplasia. Circulation 3:339–351PubMed

94.

Nemerson Y, Esnouf MP (1973) Activation of a proteolytic system by a membrane lipoprotein: mechanism of action of tissue factor. Proc Natl Acad Sci USA 70:310–314PubMedCrossRef

95.

Davie EW, Ratnoff OD (1964) Waterfall sequence for intrinsic blood clotting. Science 145:1310–1312PubMedCrossRef

96.

Macfarlane RG (1964) An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 202:498–499PubMedCrossRef

97.

Senior RM, Skogen WF, Griffin GL, Wilner GD (1986) Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B. J Clin Invest 77:1014–1019PubMedCrossRef

98.

Zimmerman GA, McIntyre TM, Prescott SM (1985) Thrombin stimulates the adherence of neutrophils to human endothelial cells in vitro. J Clin Invest 76:2235–2246PubMedCrossRef

99.

Cooper JA, Solano SJ, Bizios R, Kaplan JE, Malik AB (1984) Pulmonary neutrophil kinetics after thrombin-induced intravascular coagulation. J Appl Physiol 57:826–832PubMed

100.

Pisano JJ, Finlayson JS, Peyton MP (1968) Cross-link in fibrin polymerized by factor 13: epsilon-(gamma-glutamyl)lysine. Science 160:892–893PubMedCrossRef

101.

Furie B, Furie BC (2008) Mechanisms of thrombus formation. N Engl J Med 359:938–949PubMedCrossRef

102.

Bakker WW, Willink EJ, Donga J, Hulstaert CE, Hardonk MJ (1987) Antithrombotic activity of glomerular adenosine diphosphatase in the glomerular basement membrane of the rat kidney. J Lab Clin Med 109:171–177PubMed

103.

Nieuwenhuizen W, Vermond A, Voskuilen M, Traas DW, Verheijen JH (1983) Identification of a site in fibrin(ogen) which is involved in the acceleration of plasminogen activation by tissue-type plasminogen activator. Biochim Biophys Acta 748:86–92PubMedCrossRef

104.

Loeb L (1903) The influence of certain bacteria on the coagulation of the blood. J Med Res 10:407–419PubMed

105.

Kolle W, Otto R (1902) Die Differenzierung der Staphylokokken mittelst der Agglutination. Z Hyg 41:369–379

106.

Birch-Hirschfeld L (1934) Über die Agglutination von Staphylokokken durch Bestandteile des Säugetierblutplasmas. Klinische Woschenschrift 13

107.

Hawiger J, Timmons S, Strong DD, Cottrell BA, Riley M, Doolittle RF (1982) Identification of a region of human fibrinogen interacting with staphylococcal clumping factor. Biochemistry 21:1407–1413PubMedCrossRef

108.

Friedrich R, Panizzi P, Fuentes-Prior P, Richter K, Verhamme I, Anderson PJ, Kawabata S, Huber R, Bode W, Bock PE (2003) Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation. Nature 425:535–539PubMedCrossRef

109.

Kroh HK, Panizzi P, Bock PE (2009) Von Willebrand factor-binding protein is a hysteretic conformational activator of prothrombin. Proc Natl Acad Sci USA 106:7786–7791PubMedCrossRef

110.

McDevitt D, Francois P, Vaudaux P, Foster TJ (1994) Molecular characterization of the clumping factor (fibrinogen receptor) of Staphylococcus aureus. Mol Microbiol 11:237–248PubMedCrossRef

111.

Strong DD, Laudano AP, Hawiger J, Doolittle RF (1982) Isolation, characterization, and synthesis of peptides from human fibrinogen that block the staphylococcal clumping reaction and construction of a synthetic clumping particle. Biochemistry 21:1414–1420PubMedCrossRef

112.

Smith W, Hale JH, Smith MM (1947) The role of coagulase in staphylococcal infections. Br J Exp Pathol 28:57–67PubMed

113.

Ekstedt RD, Yotis WW (1960) Studies on staphylococci. II. Effect of coagulase on the virulence of coagulase negative strains. J Bacteriol 80:496–500PubMed

114.

Duthie ES, Lorenz LL (1952) Staphylococcal coagulase; mode of action and antigenicity. J Gen Microbiol 6:95–107PubMed

115.

Hemker HC, Bas BM, Muller AD (1975) Activation of a pro-enzyme by a stoichiometric reaction with another protein. The reaction between prothrombin and staphylocoagulase. Biochim Biophys Acta 379:180–188PubMed

116.

Kaida S, Miyata T, Yoshizawa Y, Kawabata S, Morita T, Igarashi H, Iwanaga S (1987) Nucleotide sequence of the staphylocoagulase gene: its unique COOH-terminal 8 tandem repeats. J Biochem 102:1177–1186PubMed

117.

Phonimdaeng P, O'Reilly M, Nowlan P, Bramley AJ, Foster TJ (1990) The coagulase of Staphylococcus aureus 8325–4. Sequence analysis and virulence of site-specific coagulase-deficient mutants. Mol Microbiol 4:393–404PubMedCrossRef

118.

Phonimdaeng P, O'Reilly M, O'Toole PW, Foster TJ (1988) Molecular cloning and expression of the coagulase gene of Staphylococcus aureus 8325–4. J Gen Microbiol 134:75–83PubMed

119.

Bjerketorp J, Jacobsson K, Frykberg L (2004) The von Willebrand factor-binding protein (vWbp) of Staphylococcus aureus is a coagulase. FEMS Microbiol Lett 234:309–314PubMedCrossRef

120.

Bjerketorp J, Nilsson M, Ljungh A, Flock JI, Jacobsson K, Frykberg L (2002) A novel von Willebrand factor binding protein expressed by Staphylococcus aureus. Microbiology 148:2037–2044PubMed

121.

Panizzi P, Friedrich R, Fuentes-Prior P, Richter K, Bock PE, Bode W (2006) Fibrinogen substrate recognition by staphylocoagulase. (pro)thrombin complexes. J Biol Chem 281:1179–1187PubMedCrossRef

122.

Tager M, Drummond MC (1965) Staphylocoagulase. Ann N Y Acad Sci 128:92–111PubMedCrossRef

123.

Di Nisio M, Middeldorp S, Buller HR (2005) Direct thrombin inhibitors. N Engl J Med 353:1028–1040PubMedCrossRef

124.

Vanassche T, Verhaegen J, Peetermans WE, Hoylaerts MF, Verhamme P Dabigatran inhibits Staphylococcus aureus coagulase activity. J Clin Microbiol 48:4248–50

125.

Panizzi P, Friedrich R, Fuentes-Prior P, Kroh HK, Briggs J, Tans G, Bode W, Bock PE (2006) Novel fluorescent prothrombin analogs as probes of staphylocoagulase–prothrombin interactions. J Biol Chem 281:1169–1178PubMedCrossRef

126.

Baddour LM, Tayidi MM, Walker E, McDevitt D, Foster TJ (1994) Virulence of coagulase-deficient mutants of Staphylococcus aureus in experimental endocarditis. J Med Microbiol 41:259–263PubMedCrossRef

127.

Hasegawa N, Kondo I, Hoshina S, Kurosaka K, Igarashi H (1983) Effect of highly purified coagulase and culture filtrate on virulence and immunity of a coagulase-negative mutant of Staphylococcus aureus BB. Infect Immun 39:1236–1242PubMed

128.

Jonsson P, Lindberg M, Haraldsson I, Wadstrom T (1985) Virulence of Staphylococcus aureus in a mouse mastitis model: studies of alpha hemolysin, coagulase, and protein A as possible virulence determinants with protoplast fusion and gene cloning. Infect Immun 49:765–769PubMed

129.

Seki K, Ogasawara M, Sakurada J, Murai M, Masuda S (1989) Altered virulence of a pleiotropic Staphylococcus aureus mutant with a low producibility of coagulase and other factors in mice. Microbiol Immunol 33:981–990PubMed

130.

Moreillon P, Entenza JM, Francioli P, McDevitt D, Foster TJ, Francois P, Vaudaux P (1995) Role of Staphylococcus aureus coagulase and clumping factor in pathogenesis of experimental endocarditis. Infect Immun 63:4738–4743PubMed

131.

Sawai T, Tomono K, Yanagihara K, Yamamoto Y, Kaku M, Hirakata Y, Koga H, Tashiro T, Kohno S (1997) Role of coagulase in a murine model of hematogenous pulmonary infection induced by intravenous injection of Staphylococcus aureus enmeshed in agar beads. Infect Immun 65:466–471PubMed

132.

Cheng AG, McAdow M, Kim HK, Bae T, Missiakas DM, Schneewind O Contribution of coagulases towards Staphylococcus aureus disease and protective immunity. PLoS Pathog 6:e1001036.

133.

Panizzi P, Nahrendorf M, Figueiredo JL, Panizzi J, Marinelli B, Iwamoto Y, Keliher E, Maddur AA, Waterman P, Kroh HK et al In vivo detection of Staphylococcus aureus endocarditis by targeting pathogen-specific prothrombin activation. Nat Med 17:1142–1146

134.

Ganesh VK, Rivera JJ, Smeds E, Ko YP, Bowden MG, Wann ER, Gurusiddappa S, Fitzgerald JR, Hook M (2008) A structural model of the Staphylococcus aureus ClfA–fibrinogen interaction opens new avenues for the design of anti-staphylococcal therapeutics. PLoS Pathog 4:e1000226PubMedCrossRef

135.

McDevitt D, Francois P, Vaudaux P, Foster TJ (1995) Identification of the ligand-binding domain of the surface-located fibrinogen receptor (clumping factor) of Staphylococcus aureus. Mol Microbiol 16:895–907PubMedCrossRef

136.

McDevitt D, Nanavaty T, House-Pompeo K, Bell E, Turner N, McIntire L, Foster T, Hook M (1997) Characterization of the interaction between the Staphylococcus aureus clumping factor (ClfA) and fibrinogen. Eur J Biochem 247:416–424PubMedCrossRef

137.

Walsh EJ, Miajlovic H, Gorkun OV, Foster TJ (2008) Identification of the Staphylococcus aureus MSCRAMM clumping factor B (ClfB) binding site in the alphaC-domain of human fibrinogen. Microbiology 154:550–558PubMedCrossRef

138.

McAdow M, Kim HK, DeDent AC, Hendrickx APA, Missiakas DM, Schneewind O (2011) Preventing Staphylococcus aureus sepsis through the inhibition of its agglutination in blood. PLoS Pathog [Epub ahead of print]

139.

Hall AE, Domanski PJ, Patel PR, Vernachio JH, Syribeys PJ, Gorovits EL, Johnson MA, Ross JM, Hutchins JT, Patti JM (2003) Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A. Infect Immun 71:6864–6870PubMedCrossRef

140.

Vernachio J, Bayer AS, Le T, Chai YL, Prater B, Schneider A, Ames B, Syribeys P, Robbins J, Patti JM (2003) Anti-clumping factor A immunoglobulin reduces the duration of methicillin-resistant Staphylococcus aureus bacteremia in an experimental model of infective endocarditis. Antimicrob Agents Chemother 47:3400–3406PubMedCrossRef

141.

Weems JJ Jr, Steinberg JP, Filler S, Baddley JW, Corey GR, Sampathkumar P, Winston L, John JF, Kubin CJ, Talwani R et al (2006) Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 50:2751–2755PubMedCrossRef

142.

Hair PS, Echague CG, Sholl AM, Watkins JA, Geoghegan JA, Foster TJ, Cunnion KM Clumping factor A interaction with complement factor I increases C3b cleavage on the bacterial surface of Staphylococcus aureus and decreases complement-mediated phagocytosis. Infect Immun 78:1717–1727

143.

Donahue JP, Patel H, Anderson WF, Hawiger J (1994) Three-dimensional structure of the platelet integrin recognition segment of the fibrinogen gamma chain obtained by carrier protein-driven crystallization. Proc Natl Acad Sci USA 91:12178–12182PubMedCrossRef

144.

Ware S, Donahue JP, Hawiger J, Anderson WF (1999) Structure of the fibrinogen gamma-chain integrin binding and factor XIIIa cross-linking sites obtained through carrier protein driven crystallization. Protein Sci 8:2663–2671PubMedCrossRef

145.

Foster TJ (2005) Immune evasion by staphylococci. Nat Rev Microbiol 3:948–958PubMedCrossRef

146.

Gallin JI (1991) Interferon-gamma in the management of chronic granulomatous disease. Rev Infect Dis 13:973–978PubMedCrossRef

147.

Hair PS, Ward MD, Semmes OJ, Foster TJ, Cunnion KM (2008) Staphylococcus aureus clumping factor A binds to complement regulator factor I and increases factor I cleavage of C3b. J Infect Dis 198:125–133PubMedCrossRef

148.

Rooijakkers SH, Wu J, Ruyken M, van Domselaar R, Planken KL, Tzekou A, Ricklin D, Lambris JD, Janssen BJ, van Strijp JA et al (2009) Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat Immunol 10:721–727PubMedCrossRef

149.

Chen H, Ricklin D, Hammel M, Garcia BL, McWhorter WJ, Sfyroera G, Wu YQ, Tzekou A, Li S, Geisbrecht BV et al Allosteric inhibition of complement function by a staphylococcal immune evasion protein. Proc Natl Acad Sci USA 107:17621–17626

150.

Postma B, Kleibeuker W, Poppelier MJ, Boonstra M, Van Kessel KP, Van Strijp JA, de Haas CJ (2005) Residues 10–18 within the C5a receptor N terminus compose a binding domain for chemotaxis inhibitory protein of Staphylococcus aureus. J Biol Chem 280:2020–2027PubMedCrossRef

151.

Thammavongsa V, Kern JW, Missiakas DM, Schneewind O (2009) Staphylococcus aureus synthesizes adenosine to escape host immune responses. J Exp Med 206:2417–2427PubMedCrossRef

152.

Thakker M, Park JS, Carey V, Lee JC (1998) Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model. Infect Immun 66:5183–5189PubMed

153.

Nilsson IM, Lee JC, Bremell T, Ryden C, Tarkowski A (1997) The role of staphylococcal polysaccharide microcapsule expression in septicemia and septic arthritis. Infect Immun 65:4216–4221PubMed

154.

Megiovanni AM, Sanchez F, Robledo-Sarmiento M, Morel C, Gluckman JC, Boudaly S (2006) Polymorphonuclear neutrophils deliver activation signals and antigenic molecules to dendritic cells: a new link between leukocytes upstream of T lymphocytes. J Leukoc Biol 79:977–988PubMedCrossRef

155.

van Gisbergen KP, Sanchez-Hernandez M, Geijtenbeek TB, van Kooyk Y (2005) Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN. J Exp Med 201:1281–1292PubMedCrossRef

156.

Abi Abdallah DS, Egan CE, Butcher BA, Denkers EY (2011) Mouse neutrophils are professional antigen-presenting cells programmed to instruct Th1 and Th17 T-cell differentiation. Int Immunol 23:317–326PubMedCrossRef

157.

Yang CW, Strong BS, Miller MJ, Unanue ER (2010) Neutrophils influence the level of antigen presentation during the immune response to protein antigens in adjuvants. J Immunol 185:2927–2934PubMedCrossRef

158.

Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT (1996) C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271:348–350PubMedCrossRef

159.

Fischer MB, Goerg S, Shen L, Prodeus AP, Goodnow CC, Kelsoe G, Carroll MC (1998) Dependence of germinal center B cells on expression of CD21/CD35 for survival. Science 280:582–585PubMedCrossRef

160.

Thornton BP, Vetvicka V, Ross GD (1996) Function of C3 in a humoral response: iC3b/C3dg bound to an immune complex generated with natural antibody and a primary antigen promotes antigen uptake and the expression of co-stimulatory molecules by all B cells, but only stimulates immunoglobulin synthesis by antigen-specific B cells. Clin Exp Immunol 104:531–537PubMedCrossRef

161.

Kopf M, Abel B, Gallimore A, Carroll M, Bachmann MF (2002) Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat Med 8:373–378PubMedCrossRef

162.

Lambris JD, Ricklin D, Geisbrecht BV (2008) Complement evasion by human pathogens. Nat Rev Microbiol 6:132–142PubMedCrossRef

163.

Sahu A, Kozel TR, Pangburn MK (1994) Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation. Biochem J 302(Pt 2):429–436PubMed

164.

Langley R, Wines B, Willoughby N, Basu I, Proft T, Fraser JD (2005) The staphylococcal superantigen-like protein 7 binds IgA and complement C5 and inhibits IgA-Fc alpha RI binding and serum killing of bacteria. J Immunol 174:2926–2933PubMed

165.

Atkins KL, Burman JD, Chamberlain ES, Cooper JE, Poutrel B, Bagby S, Jenkins AT, Feil EJ, van den Elsen JM (2008) S. aureus IgG-binding proteins SpA and Sbi: host specificity and mechanisms of immune complex formation. Mol Immunol 45:1600–1611PubMedCrossRef

166.

Sjodahl J (1977) Repetitive sequences in protein A from Staphylococcus aureus. Arrangement of five regions within the protein, four being highly homologous and Fc-binding. Eur J Biochem 73:343–351PubMedCrossRef

167.

Haupt K, Reuter M, van den Elsen J, Burman J, Halbich S, Richter J, Skerka C, Zipfel PF (2008) The Staphylococcus aureus protein Sbi acts as a complement inhibitor and forms a tripartite complex with host complement Factor H and C3b. PLoS Pathog 4:e1000250PubMedCrossRef

168.

Toapanta FR, Ross TM (2006) Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity. Immunol Res 36:197–210PubMedCrossRef

169.

Ricklin D, Tzekou A, Garcia BL, Hammel M, McWhorter WJ, Sfyroera G, Wu YQ, Holers VM, Herbert AP, Barlow PN et al (2009) A molecular insight into complement evasion by the staphylococcal complement inhibitor protein family. J Immunol 183:2565–2574PubMedCrossRef

170.

Jongerius I, Kohl J, Pandey MK, Ruyken M, van Kessel KP, van Strijp JA, Rooijakkers SH (2007) Staphylococcal complement evasion by various convertase-blocking molecules. J Exp Med 204:2461–2471PubMedCrossRef

171.

Isenman DE, Leung E, Mackay JD, Bagby S, van den Elsen JM (2010) Mutational analyses reveal that the staphylococcal immune evasion molecule Sbi and complement receptor 2 (CR2) share overlapping contact residues on C3d: implications for the controversy regarding the CR2/C3d cocrystal structure. J Immunol 184:1946–1955PubMedCrossRef

172.

Edwards CK 3rd, Watts LM, Parmely MJ, Linnik MD, Long RE, Borcherding DR (1994) Effect of the carbocyclic nucleoside analogue MDL 201,112 on inhibition of interferon-gamma-induced priming of Lewis (LEW/N) rat macrophages for enhanced respiratory burst and MHC class II Ia+ antigen expression. J Leukoc Biol 56:133–144PubMed

173.

Panther E, Idzko M, Herouy Y, Rheinen H, Gebicke-Haerter PJ, Mrowietz U, Dichmann S, Norgauer J (2001) Expression and function of adenosine receptors in human dendritic cells. FASEB J 15:1963–1970PubMedCrossRef

174.

Hasko G, Kuhel DG, Chen JF, Schwarzschild MA, Deitch EA, Mabley JG, Marton A, Szabo C (2000) Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J 14:2065–2074PubMedCrossRef

175.

Schneewind O, Fowler A, Faull KF (1995) Structure of the cell wall anchor of surface proteins in Staphylococcus aureus. Science 268:103–106PubMedCrossRef

176.

Guss B, Uhlen M, Nilsson B, Lindberg M, Sjoquist J, Sjodahl J (1984) Region X, the cell-wall-attachment part of staphylococcal protein A. Eur J Biochem 138:413–420PubMedCrossRef

177.

Lindmark R, Thoren-Tolling K, Sjoquist J (1983) Binding of immunoglobulins to protein A and immunoglobulin levels in mammalian sera. J Immunol Methods 62:1–13PubMedCrossRef

178.

Sasso EH, Silverman GJ, Mannik M (1989) Human IgM molecules that bind staphylococcal protein A contain VHIII H chains. J Immunol 142:2778–2783PubMed

179.

Hartleib J, Kohler N, Dickinson RB, Chhatwal GS, Sixma JJ, Hartford OM, Foster TJ, Peters G, Kehrel BE, Herrmann M (2000) Protein A is the von Willebrand factor binding protein on Staphylococcus aureus. Blood 96:2149–2156PubMed

180.

Nguyen T, Ghebrehiwet B, Peerschke EI (2000) Staphylococcus aureus protein A recognizes platelet gC1qR/p33: a novel mechanism for staphylococcal interactions with platelets. Infect Immun 68:2061–2068PubMedCrossRef

181.

Gomez MI, Lee A, Reddy B, Muir A, Soong G, Pitt A, Cheung A, Prince A (2004) Staphylococcus aureus protein A induces airway epithelial inflammatory responses by activating TNFR1. Nat Med 10:842–848PubMedCrossRef

182.

Mazmanian SK, Ton-That H, Schneewind O (2001) Sortase-catalysed anchoring of surface proteins to the cell wall of Staphylococcus aureus. Mol Microbiol 40:1049–1057PubMedCrossRef

183.

Silverman GJ, Sasano M, Wormsley SB (1993) Age-associated changes in binding of human B lymphocytes to a VH3-restricted unconventional bacterial antigen. J Immunol 151:5840–5855PubMed

184.

Goodyear CS, Silverman GJ (2004) Staphylococcal toxin induced preferential and prolonged in vivo deletion of innate-like B lymphocytes. Proc Natl Acad Sci USA 101:11392–11397PubMedCrossRef

185.

Silverman GJ, Cary SP, Dwyer DC, Luo L, Wagenknecht R, Curtiss VE (2000) A B cell superantigen-induced persistent "Hole" in the B-1 repertoire. J Exp Med 192:87–98PubMedCrossRef

186.

Kim HK, Cheng AG, Kim HY, Missiakas DM, Schneewind O Nontoxigenic protein A vaccine for methicillin-resistant Staphylococcus aureus infections in mice. J Exp Med 207:1863–1870

187.

Kim HK, Kim HY, Schneewind O, Missiakas D Identifying protective antigens of Staphylococcus aureus, a pathogen that suppresses host immune responses. FASEB J 25:3605–3612

Titel: Exploring Staphylococcus aureus pathways to disease for vaccine development
verfasst von: Andrea DeDent
Hwan Keun Kim
Dominique Missiakas
Olaf Schneewind
Publikationsdatum: 01.03.2012
Verlag: Springer-Verlag
Erschienen in: Seminars in Immunopathology / Ausgabe 2/2012
Print ISSN: 1863-2297
Elektronische ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-011-0299-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Exploring Staphylococcus aureus pathways to disease for vaccine development

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Targeting the host–pathogen interface for treatment of Staphylococcus aureus infection

Neutrophils in innate host defense against Staphylococcus aureus infections

Development of a vaccine against Staphylococcus aureus

Metal ion acquisition in Staphylococcus aureus: overcoming nutritional immunity

Staphylococcus aureus: an introduction

Molecular basis of Staphylococcus epidermidis infections

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin